Holen Sie sich die Stockscreener-App
24.98
0.89%
0.22
Vorhandelsmarkt:
24.95
-0.03
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.76
Offen:
$24.73
24-Stunden-Volumen:
44.22M
Relative Volume:
1.11
Marktkapitalisierung:
$142.03B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.77B
KGV:
13.29
EPS:
1.88
Netto-Cashflow:
$12.44B
1W Leistung:
+0.24%
1M Leistung:
+6.34%
6M Leistung:
-5.49%
1J Leistung:
-13.89%
1-Tages-Spanne:
$24.71
$25.07
1-Wochen-Bereich:
$24.51
$25.17
52-Wochen-Spanne:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.98 | 140.77B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
735.19 | 656.73B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 426.69B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
211.92 | 371.68B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.64 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
85.48 | 210.11B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Pfizer (PFE) Volatility and Risk Allocation: Navigating a Shifting Pharmaceutical Landscape - AInvest
Pfizer's Strategic Reinvention: Execution Discipline and Risk Allocation Reshape Valuation Narrative - AInvest
Pfizer's Strategic Volatility: Tactical Entry Points and Rule-Based Trading in a Biotech Recovery - AInvest
Pfizer's Strategic Volatility: Decoding Recent Share Price Swings and Tactical Entry Points - AInvest
Pfizer's Surging Momentum: A Catalyst for Large-Cap Biotech Growth - AInvest
$33M Pfizer Antitrust Deal OK'd, First MDL Trial Date Set - Law360
Pfizer's Golden Cross and Pipeline Progress: A Dividend-Driven Turnaround or a Value-Trap Mirage? - AInvest
Pfizer's Pipeline Monetization and 7% Yield: A Dual-Engine Opportunity in a Re-Rating Pharma Landscape - AInvest
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Backtesting results for Pfizer Inc. trading strategiesTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Can Pfizer Inc. recover in the next quarterTrade Signal Summary & Daily Chart Pattern Signal Reports - Newser
Olema stock jumps after new clinical trial collaboration with Pfizer - Investing.com
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer: Pipeline Monetization Shows Great PromiseRich Yields Pending Re-Rating (NYSE:PFE) - Seeking Alpha
Healthcare Valuations Near Multi-Year Lows Suggest Risk–Reward Asymmetry - Investing.com
Is Pfizer Stock Underperforming The Nasdaq? - Barchart.com
Olema Pharmaceuticals, Pfizer Collaborate for Clinical Trial of Breast Cancer Treatment - MarketScreener
Olema Pharmaceuticals Partners with Pfizer for New Trial - TipRanks
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer - The Manila Times
Pfizer, Moderna in focus as Trump demands answers on COVID success - Seeking Alpha
Olema Oncology Announces New Clinical Trial Agreement with - GlobeNewswire
Novel Breast Cancer Treatment: Olema and Pfizer Join Forces on Promising Drug Combination Study - Stock Titan
Is Pfizer Inc. reversing from oversold territoryJuly 2025 Action & Smart Allocation Stock Tips - Newser
Pfizer (PFE) Valuation in Focus Following FDA Approval of Updated COVID-19 Vaccine - simplywall.st
Stock Analysis | Pfizer OutlookMixed Signals as Technicals Deter and Fundamentals Stay Strong - AInvest
Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide - Yahoo Finance
Trump Demands Pfizer, Other Covid Drug Makers To… - inkl
Unit Dose Packaging Market Top Companies StudyPfizer Inc., - openPR.com
Is Pfizer Inc. trending in predictive chart modelsWeekly Profit Summary & Real-Time Buy Signal Notifications - Newser
Advanced analytics toolkit walkthrough for Pfizer Inc.Quarterly Market Summary & Expert Approved Momentum Ideas - Newser
How to read the order book for Pfizer Inc.July 2025 Weekly Recap & Weekly High Potential Alerts - Newser
Pfizer's Golden Cross Signals Strength: How to Play the Stock - Yahoo Finance
A Look at Pfizer’s Valuation After FDA Approval of Next-Gen COVID Vaccine for Older Adults and High-Risk Groups - Yahoo Finance
Chart overlay techniques for tracking Pfizer Inc.Weekly Gains Report & Verified Swing Trading Watchlist - Newser
Relative strength of Pfizer Inc. in sector analysisIPO Watch & Long-Term Investment Growth Plans - Newser
Using flow based indicators on Pfizer Inc.Earnings Recap Summary & Reliable Entry Point Trade Alerts - Newser
Pfizer Inc. Rebound Backed by Sentiment Shift getLinesFromResByArray error: size == 0 - thegnnews.com
Should FDA Approval of Updated COVID Vaccine for Vulnerable Groups Prompt a Closer Look at Pfizer (PFE)? - simplywall.st
Pfizer Inc. - Britannica
Pfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine - MSN
Price momentum metrics for Pfizer Inc. explainedPortfolio Value Report & AI Powered Market Trend Analysis - Newser
Developing predictive dashboards with Pfizer Inc. dataEarnings Overview Report & Daily Profit Maximizing Trade Tips - Newser
Published on: 2025-08-30 04:48:26 - Newser
Better High-Yielding Dividend Stock: Realty Income vs. Pfizer - The Globe and Mail
Pfizer Sued Over Depo-Provera Brain Tumor Risks - Law360
UPC sees rising small molecule litigation with Pfizer in the hot seat - Life Sciences Intellectual Property Review
Measuring Pfizer Inc.’s beta against major indicesMarket Rally & Smart Investment Allocation Tips - Newser
Moderna and Freshfields win against BioNTech and Pfizer at UK Court of Appeal - JUVE Patent
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):